预测治疗药物监测临床实用性的评分:在肿瘤口服分子靶向治疗中的应用
本研究基于标准TDM推荐提取关键参数,构建量化评分以预测口服分子靶向治疗(oMTT)开展TDM的临床实用性。截至2021年9月1日FDA批准的67种oMTT评分范围15(acalabrutinib)至80(sunitinib),平均48.3、标准差15.6,并按<40、≥40且<60、≥60分为低、中、高相关性。阴性对照评分多在40左右或以下,阳性对照在不同适应症中评分较高。
要点
- 该评分可量化比较oMTT开展TDM的潜在实用性,高分药物应优先考虑TDM。
- 评分涵盖暴露变异性、技术复杂性、疗效与安全性四类参数。
- 按评分将TDM相关性分为低(<40)、中(≥40且<60)、高(≥60)三档。
核心结论
- 提出一种可重复的量化评分,用于比较口服分子靶向治疗开展TDM的潜在实用性,未来指南应优先对评分最高的药物开展TDM。
研究设计与样本
- 从标准TDM推荐中识别oMTT适合TDM的关键参数,并收集oMTT药理学数据进行评分。
- 截至2021年9月1日,FDA批准用于肿瘤血液适应症的oMTT共67种。
- 通过评估肿瘤及其他领域中已有前瞻性验证或强TDM推荐的药物,验证评分有效性并定义相关阈值。
主要发现
- 67种oMTT评分范围15(acalabrutinib)至80(sunitinib),平均48.3,标准差15.6。
- 评分最高的药物包括sunitinib、sorafenib、cabozantinib、nilotinib和abemaciclib。
- 阴性对照评分一般在40左右或以下,阳性对照在不同适应症中评分较高。
关键数值与推荐
- 评分参数覆盖暴露变异性(考虑食物和质子泵抑制剂的PK影响)、技术复杂性(PK线性和活性代谢物)、疗效(暴露-反应关系)和安全性(最大耐受剂量和暴露-安全性关系)。
- 按评分将TDM相关性分为低(<40)、中(≥40且<60)、高(≥60)三档。
临床怎么用
- 临床可参考该评分对oMTT进行TDM优先级排序,评分≥60的药物更可能需要TDM支持剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic drug monitoring (TDM) involves measuring and interpreting drug concentrations in biological fluids to adjust drug dosages. In onco-hematology, TDM guidelines for oral molecular targeted therapies (oMTTs) are varied. This study evaluates a quantitative approach with a score to predict the clinical usefulness of TDM for oMTTs. We identified key parameters for an oMTT's suitability for TDM from standard TDM recommendations. We gathered oMTT pharmacological data, which covered exposure variability (considering pharmacokinetic (PK) impact of food and proton pump inhibitors), technical intricacy (PK linearity and active metabolites), efficacy (exposure-response relationship), and safety (maximum tolerated dose, and exposure-safety relationship). To assess the validity and the relevance of the score and define relevant thresholds, we evaluated molecules with prospective validation or strong recommendations for TDM, both in oncology and in other fields. By September 1, 2021, the US Food and Drug Administration (FDA) approved 67 oMTTs for onco-hematological indications. Scores ranged from 15 (acalabrutinib) to 80 (sunitinib) with an average of 48.3 and a standard deviation of 15.6. Top scorers included sunitinib, sorafenib, cabozantinib, nilotinib, and abemaciclib. Based on scores, drugs were categorized into low (< 40), intermediate (≥ 40 and < 60), and high (≥ 60) relevance for TDM. Notably, negative controls generally scored around or under 40, whereas positive controls had a high score across different indications. In this work, we propose a quantitative and reproducible score to compare the potential usefulness of TDM for oMTTs. Future guidelines should prioritize the TDM for molecules with the highest score.
引用
- Géraud A, Combarel D, Funck-Brentano C, et al. A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer. Clin Pharmacol Ther. 2024. PMID: 38389482. doi:10.1002/cpt.3193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。